Table 3.
Frequency of complications.
| Total* | GEM-CIS | GEM-CARBO | Docetaxel | |
|---|---|---|---|---|
| Total patients, No. (%) | 96 | 51 | 36 | 9 |
| Total grade 3 complications, No. (%) | 88 | 45 | 37 | 6 |
| Anemia (transfusion required) | 34 | 16 | 17 | 1 |
| Fever, severe (hospitalization) | 25 | 16 | 7 | 2 |
| Thromboembolic Event | 9 | 7 | 2 | 0 |
| Other | 20 | 6 | 11 | 3 |
| Total grade 4 complications, No. (%) | 11 | 6 | 4 | 1 |
| Fever, life threatening | 1 | 1 | 0 | 0 |
| Gastro-intestinal bleeding | 5 | 2 | 2 | 1 |
| Thromboembolic Event | 2 | 2 | 0 | 0 |
| Myocardial Infarction | 1 | 1 | 0 | 0 |
| Other | 2 | 0 | 2 | 0 |
| Grade 5 complications, No. (%) | 4 | 0 | 4 | 0 |
| Sepsis | 3 | 0 | 3 | 0 |
| Myocardial Infarction | 1 | 0 | 1 | 0 |
CTCAE common terminology criteria for adverse events, GEM-CIS Gemcitabine/Cisplatin, GEM-CARBO Gemcitabine/Carboplatin.
*Total is more than 100% due to all grade 3–5 complications being calculated, whereas some patients had multiple complications.